27/03/2024

Motilent’s EntrolyticsMD is now ready for clinical use in the United States.

EntrolyticsMD, the world's first imaging platform for digestive diseases has been listed with the FDA. 40 Million people are affected by digestive diseases (including inflammatory bowel disease and GI cancers) costing $119.6 billion in 2018. EntrolyticsMD is already in use across over 300 investigator projects, for AI deployment and in clinical trials.

16/02/2024

Motilent Monthly Digest #10

✈️ Motilent at ECCO - Bowel Wall Thickness or Bowel Wall Volume?!

25/11/2024

Motilent Monthly Digest #9

EntrolyticsMD, the world's first imaging platform for digestive diseases has been listed with the FDA.

10/04/2023

Motilent Monthly Digest #8

Endoscopy is now available on Entrolytics. In the cloud, on-demand, and with in-built structured reporting (right next to other tests!!)

Innovation at Motilent never stops.

Change the way you see the gut - get in touch today Get in touch